APO Research
Talk to an analyst

APO RESEARCH · REPORT

Viral Vector and Plasmid DNA

Viral vectors carry genetic material into cells by exploiting the molecular mechanisms by which viruses transmit their genomes to other cells for infection.It can occur in vivo or in vitro.Plasmid carriers are plasmids artificially constructed on the basis of natural plasmids to adapt to laboratory operations.In recent years, global viral vector and plasmid DNA manufacturing has developed rapidly, with a compound growth rate of about 28% during 2018-2018.In 2018, global sales of viral vector and plasmid DNA production reached $381 million.In 2018, China accounted for about 4% of global sales.In the next five years, the production of viral vectors and plasmid DNA products in China will continue to grow rapidly.Viral vector and plasmid DNA manufacturing are mainly divided into viral vector manufacturing and plasmid DNA manufacturing, among which viral vector manufacturing accounts for the largest proportion, accounting for nearly 38% of the total market in 2018.Viral vector and plasmid DNA manufacturing is mainly used for drug development and production of cancer, genetic diseases, viral infections and other diseases, among which cancer is the main application field, accounting for 35% in 2018.The market is highly competitive.Brammer Bio, Oxford BioMedica, Cobra Biologics, FinVector and Lonza are major suppliers.They have mastered key technologies and patents, and they have a fixed customer base. They have established a monopoly in the market.Gene therapy technology innovation and clinical trials have mushroomed in recent years, and a number of gene therapy projects have been approved for marketing in the United States, the European Union, China and other countries.The target of gene therapy has also been gradually expanded from single gene genetic diseases to malignant tumors, infectious diseases, cardiovascular diseases, autoimmune diseases, metabolic diseases and other major diseases.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Viral vectors carry genetic material into cells by exploiting the molecular mechanisms by which viruses transmit their genomes to other cells for infection.It can occur in vivo or in vitro.Plasmid carriers are plasmids artificially constructed on the basis of natural plasmids to adapt to laboratory operations.In recent years, global viral vector and plasmid DNA manufacturing has developed rapidly, with a compound growth rate of about 28% during 2018-2018.In 2018, global sales of viral vector and plasmid DNA production reached $381 million.In 2018, China accounted for about 4% of global sales.In the next five years, the production of viral vectors and plasmid DNA products in China will continue to grow rapidly.Viral vector and plasmid DNA manufacturing are mainly divided into viral vector manufacturing and plasmid DNA manufacturing, among which viral vector manufacturing accounts for the largest proportion, accounting for nearly 38% of the total market in 2018.Viral vector and plasmid DNA manufacturing is mainly used for drug development and production of cancer, genetic diseases, viral infections and other diseases, among which cancer is the main application field, accounting for 35% in 2018.The market is highly competitive.Brammer Bio, Oxford BioMedica, Cobra Biologics, FinVector and Lonza are major suppliers.They have mastered key technologies and patents, and they have a fixed customer base. They have established a monopoly in the market.Gene therapy technology innovation and clinical trials have mushroomed in recent years, and a number of gene therapy projects have been approved for marketing in the United States, the European Union, China and other countries.The target of gene therapy has also been gradually expanded from single gene genetic diseases to malignant tumors, infectious diseases, cardiovascular diseases, autoimmune diseases, metabolic diseases and other major diseases.

Selected research

Market Analysis & Forecast

Global Viral Vector and Plasmid DNA Market Analysis and Forecast 2026-2032

28 December 2025210 pages

Choose your research edition.

Industry ResearchViral Vector and Plasmid DNA Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Viral Vector and Plasmid DNA Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Viral Vector and Plasmid DNA Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Viral Vector and Plasmid DNA Market Outlook and Growth Opportunities 2026210 pages · $4,250 USDMarket Analysis & ForecastGlobal Viral Vector and Plasmid DNA Market Analysis and Forecast 2026-2032210 pages · $4,950 USD

Market perspective

Viral vectors carry genetic material into cells by exploiting the molecular mechanisms by which viruses transmit their genomes to other cells for infection.It can occur in vivo or in vitro.Plasmid carriers are plasmids artificially constructed on the basis of natural plasmids to adapt to laboratory operations.In recent years, global viral vector and plasmid DNA manufacturing has developed rapidly, with a compound growth rate of about 28% during 2018-2018.In 2018, global sales of viral vector and plasmid DNA production reached $381 million.In 2018, China accounted for about 4% of global sales.In the next five years, the production of viral vectors and plasmid DNA products in China will continue to grow rapidly.Viral vector and plasmid DNA manufacturing are mainly divided into viral vector manufacturing and plasmid DNA manufacturing, among which viral vector manufacturing accounts for the largest proportion, accounting for nearly 38% of the total market in 2018.Viral vector and plasmid DNA manufacturing is mainly used for drug development and production of cancer, genetic diseases, viral infections and other diseases, among which cancer is the main application field, accounting for 35% in 2018.The market is highly competitive.Brammer Bio, Oxford BioMedica, Cobra Biologics, FinVector and Lonza are major suppliers.They have mastered key technologies and patents, and they have a fixed customer base. They have established a monopoly in the market.Gene therapy technology innovation and clinical trials have mushroomed in recent years, and a number of gene therapy projects have been approved for marketing in the United States, the European Union, China and other countries.The target of gene therapy has also been gradually expanded from single gene genetic diseases to malignant tumors, infectious diseases, cardiovascular diseases, autoimmune diseases, metabolic diseases and other major diseases.

Global Viral Vector and Plasmid DNA key players include BioReliance, Oxford BioMedica, UniQure, Cobra Biologics, etc. Global top four manufacturers hold a share over 45%.

North America is the largest market, with a share about 50%, followed by Europe, and Asia-Pacific, both have a share over 40 percent.

Read the full market overview

In terms of product, Viral Vectors is the largest segment, with a share about 80%. And in terms of application, the largest application is Cancers, followed by Inherited Disorders, Viral Infections, etc.

Report Includes

This report presents an overview of global market for Viral Vector and Plasmid DNA, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Viral Vector and Plasmid DNA, also provides the revenue of main regions and countries. Of the upcoming market potential for Viral Vector and Plasmid DNA, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Viral Vector and Plasmid DNA revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Viral Vector and Plasmid DNA market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Viral Vector and Plasmid DNA revenue, projected growth trends, production technology, application and end-user industry.

Viral Vector and Plasmid DNA Segment by Company

Brammer Bio

Oxford BioMedica

Cobra Biologics

FinVector

Lonza

BioReliance

MolMed

FUJIFILM Diosynth Biotechnologies

UniQure

Aldevron

Richter-Helm

Eurogentec

OBiO Technology

Yposkesi

Cell and Gene Therapy Catapult

MassBiologics

Biovian

VGXI

Gene Synthesis

PlasmidFactory

Jikai Gene

Viral Vector and Plasmid DNA Segment by Type

Plasmid DNA

Viral Vector

Viral Vector and Plasmid DNA Segment by Application

Cancer

Virus Infection

Hereditary Disease

Viral Vector and Plasmid DNA Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Vector and Plasmid DNA market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Viral Vector and Plasmid DNA and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Vector and Plasmid DNA.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Viral Vector and Plasmid DNA in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Viral Vector and Plasmid DNA company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Viral Vector and Plasmid DNA revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Viral Vector and Plasmid DNA Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Plasmid DNA Major Player Table 3. Viral Vector Major Player Table 4. Global Viral Vector and Plasmid DNA Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Cancer Major Player Table 6. Virus Infection Major Player Table 7. Hereditary Disease Major Player Table 8. Viral Vector and Plasmid DNA Industry Trends Table 9. Viral Vector and Plasmid DNA Industry Drivers Table 10. Viral Vector and Plasmid DNA Industry Opportunities and Challenges Table 11. Viral Vector and Plasmid DNA Industry Restraints Table 12. Global Viral Vector and Plasmid DNA Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Viral Vector and Plasmid DNA Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Viral Vector and Plasmid DNA Market Share by Region (2021-2026) Table 15. Global Viral Vector and Plasmid DNA Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Viral Vector and Plasmid DNA Market Share by Region (2027-2032) Table 17. Global Viral Vector and Plasmid DNA Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Viral Vector and Plasmid DNA Revenue Market Share by Players (2021-2026) Table 19. Global Viral Vector and Plasmid DNA Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Viral Vector and Plasmid DNA Key Players Headquarters & Area Served Table 21. Global Viral Vector and Plasmid DNA Players, Product Type & Application Table 22. Global Viral Vector and Plasmid DNA Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Viral Vector and Plasmid DNA by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Viral Vector and Plasmid DNA Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Viral Vector and Plasmid DNA Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Viral Vector and Plasmid DNA Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Viral Vector and Plasmid DNA Revenue Market Share by Type (2021-2026) Table 29. Global Viral Vector and Plasmid DNA Revenue Market Share by Type (2027-2032) Table 30. Global Viral Vector and Plasmid DNA Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Viral Vector and Plasmid DNA Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Viral Vector and Plasmid DNA Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Viral Vector and Plasmid DNA Revenue Market Share by Application (2021-2026) Table 34. Global Viral Vector and Plasmid DNA Revenue Market Share by Application (2027-2032) Table 35. Brammer Bio Company Information Table 36. Brammer Bio Business Overview Table 37. Brammer Bio Viral Vector and Plasmid DNA Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Brammer Bio Viral Vector and Plasmid DNA Product Portfolio Table 39. Brammer Bio Recent Development Table 40. Oxford BioMedica Company Information Table 41. Oxford BioMedica Business Overview Table 42. Oxford BioMedica Viral Vector and Plasmid DNA Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Oxford BioMedica Viral Vector and Plasmid DNA Product Portfolio Table 44. Oxford BioMedica Recent Development Table 45. Cobra Biologics Company Information Table 46. Cobra Biologics Business Overview Table 47. Cobra Biologics Viral Vector and Plasmid DNA Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Cobra Biologics Viral Vector and Plasmid DNA Product Portfolio Table 49. Cobra Biologics Recent Development Table 50. FinVector Company Information Table 51. FinVector Business Overview Table 52. FinVector Viral Vector and Plasmid DNA Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. FinVector Viral Vector and Plasmid DNA Product Portfolio Table 54. FinVector Recent Development Table 55. Lonza Company Information Table 56. Lonza Business Overview Table 57. Lonza Viral Vector and Plasmid DNA Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Lonza Viral Vector and Plasmid DNA Product Portfolio Table 59. Lonza Recent Development Table 60. BioReliance Company Information Table 61. BioReliance Business Overview Table 62. BioReliance Viral Vector and Plasmid DNA Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. BioReliance Viral Vector and Plasmid DNA Product Portfolio Table 64. BioReliance Recent Development Table 65. MolMed Company Information Table 66. MolMed Business Overview Table 67. MolMed Viral Vector and Plasmid DNA Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. MolMed Viral Vector and Plasmid DNA Product Portfolio Table 69. MolMed Recent Development Table 70. FUJIFILM Diosynth Biotechnologies Company Information Table 71. FUJIFILM Diosynth Biotechnologies Business Overview Table 72. FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Product Portfolio Table 74. FUJIFILM Diosynth Biotechnologies Recent Development Table 75. UniQure Company Information Table 76. UniQure Business Overview Table 77. UniQure Viral Vector and Plasmid DNA Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. UniQure Viral Vector and Plasmid DNA Product Portfolio Table 79. UniQure Recent Development Table 80. Aldevron Company Information Table 81. Aldevron Business Overview Table 82. Aldevron Viral Vector and Plasmid DNA Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Aldevron Viral Vector and Plasmid DNA Product Portfolio Table 84. Aldevron Recent Development Table 85. Richter-Helm Company Information Table 86. Richter-Helm Business Overview Table 87. Richter-Helm Viral Vector and Plasmid DNA Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Richter-Helm Viral Vector and Plasmid DNA Product Portfolio Table 89. Richter-Helm Recent Development Table 90. Eurogentec Company Information Table 91. Eurogentec Business Overview Table 92. Eurogentec Viral Vector and Plasmid DNA Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Eurogentec Viral Vector and Plasmid DNA Product Portfolio Table 94. Eurogentec Recent Development Table 95. OBiO Technology Company Information Table 96. OBiO Technology Business Overview Table 97. OBiO Technology Viral Vector and Plasmid DNA Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. OBiO Technology Viral Vector and Plasmid DNA Product Portfolio Table 99. OBiO Technology Recent Development Table 100. Yposkesi Company Information Table 101. Yposkesi Business Overview Table 102. Yposkesi Viral Vector and Plasmid DNA Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Yposkesi Viral Vector and Plasmid DNA Product Portfolio Table 104. Yposkesi Recent Development Table 105. Cell and Gene Therapy Catapult Company Information Table 106. Cell and Gene Therapy Catapult Business Overview Table 107. Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Product Portfolio Table 109. Cell and Gene Therapy Catapult Recent Development Table 110. MassBiologics Company Information Table 111. MassBiologics Business Overview Table 112. MassBiologics Viral Vector and Plasmid DNA Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. MassBiologics Viral Vector and Plasmid DNA Product Portfolio Table 114. MassBiologics Recent Development Table 115. Biovian Company Information Table 116. Biovian Business Overview Table 117. Biovian Viral Vector and Plasmid DNA Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Biovian Viral Vector and Plasmid DNA Product Portfolio Table 119. Biovian Recent Development Table 120. VGXI Company Information Table 121. VGXI Business Overview Table 122. VGXI Viral Vector and Plasmid DNA Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. VGXI Viral Vector and Plasmid DNA Product Portfolio Table 124. VGXI Recent Development Table 125. Gene Synthesis Company Information Table 126. Gene Synthesis Business Overview Table 127. Gene Synthesis Viral Vector and Plasmid DNA Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Gene Synthesis Viral Vector and Plasmid DNA Product Portfolio Table 129. Gene Synthesis Recent Development Table 130. PlasmidFactory Company Information Table 131. PlasmidFactory Business Overview Table 132. PlasmidFactory Viral Vector and Plasmid DNA Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. PlasmidFactory Viral Vector and Plasmid DNA Product Portfolio Table 134. PlasmidFactory Recent Development Table 135. Jikai Gene Company Information Table 136. Jikai Gene Business Overview Table 137. Jikai Gene Viral Vector and Plasmid DNA Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Jikai Gene Viral Vector and Plasmid DNA Product Portfolio Table 139. Jikai Gene Recent Development Table 140. North America Viral Vector and Plasmid DNA Revenue by Type (2021-2026) & (US$ Million) Table 141. North America Viral Vector and Plasmid DNA Revenue by Type (2027-2032) & (US$ Million) Table 142. North America Viral Vector and Plasmid DNA Revenue by Application (2021-2026) & (US$ Million) Table 143. North America Viral Vector and Plasmid DNA Revenue by Application (2027-2032) & (US$ Million) Table 144. North America Viral Vector and Plasmid DNA Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 145. North America Viral Vector and Plasmid DNA Revenue by Country (2021-2026) & (US$ Million) Table 146. North America Viral Vector and Plasmid DNA Revenue by Country (US$ Million) & (2027-2032) Table 147. Europe Viral Vector and Plasmid DNA Revenue by Type (2021-2026) & (US$ Million) Table 148. Europe Viral Vector and Plasmid DNA Revenue by Type (2027-2032) & (US$ Million) Table 149. Europe Viral Vector and Plasmid DNA Revenue by Application (2021-2026) & (US$ Million) Table 150. Europe Viral Vector and Plasmid DNA Revenue by Application (2027-2032) & (US$ Million) Table 151. Europe Viral Vector and Plasmid DNA Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 152. Europe Viral Vector and Plasmid DNA Revenue by Country (2021-2026) & (US$ Million) Table 153. Europe Viral Vector and Plasmid DNA Revenue by Country (US$ Million) & (2027-2032) Table 154. China Viral Vector and Plasmid DNA Revenue by Type (2021-2026) & (US$ Million) Table 155. China Viral Vector and Plasmid DNA Revenue by Type (2027-2032) & (US$ Million) Table 156. China Viral Vector and Plasmid DNA Revenue by Application (2021-2026) & (US$ Million) Table 157. China Viral Vector and Plasmid DNA Revenue by Application (2027-2032) & (US$ Million) Table 158. Asia Viral Vector and Plasmid DNA Revenue by Type (2021-2026) & (US$ Million) Table 159. Asia Viral Vector and Plasmid DNA Revenue by Type (2027-2032) & (US$ Million) Table 160. Asia Viral Vector and Plasmid DNA Revenue by Application (2021-2026) & (US$ Million) Table 161. Asia Viral Vector and Plasmid DNA Revenue by Application (2027-2032) & (US$ Million) Table 162. Asia Viral Vector and Plasmid DNA Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 163. Asia Viral Vector and Plasmid DNA Revenue by Region (US$ Million) & (2021-2026) Table 164. Asia Viral Vector and Plasmid DNA Revenue by Region (US$ Million) & (2027-2032) Table 165. SAMEA Viral Vector and Plasmid DNA Revenue by Type (2021-2026) & (US$ Million) Table 166. SAMEA Viral Vector and Plasmid DNA Revenue by Type (2027-2032) & (US$ Million) Table 167. SAMEA Viral Vector and Plasmid DNA Revenue by Application (2021-2026) & (US$ Million) Table 168. SAMEA Viral Vector and Plasmid DNA Revenue by Application (2027-2032) & (US$ Million) Table 169. SAMEA Viral Vector and Plasmid DNA Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 170. SAMEA Viral Vector and Plasmid DNA Revenue by Country (2021-2026) & (US$ Million) Table 171. SAMEA Viral Vector and Plasmid DNA Revenue by Country (US$ Million) & (2027-2032) Table 172. Research Programs/Design for This Report Table 173. Authors List of This Report Table 174. Secondary Sources Table 175. Primary Sources List of Figures Figure 1. Viral Vector and Plasmid DNA Image Figure 2. Global Viral Vector and Plasmid DNA Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Viral Vector and Plasmid DNA Market Size Share 2021 VS 2025 VS 2032 Figure 4. Plasmid DNA Image Figure 5. Viral Vector Image Figure 6. Global Viral Vector and Plasmid DNA Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Viral Vector and Plasmid DNA Market Size Share 2021 VS 2025 VS 2032 Figure 8. Cancer Image Figure 9. Virus Infection Image Figure 10. Hereditary Disease Image Figure 11. Global Viral Vector and Plasmid DNA Market Size (US$ Million) & (2021-2032) Figure 12. Global Viral Vector and Plasmid DNA Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Viral Vector and Plasmid DNA Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Viral Vector and Plasmid DNA Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Viral Vector and Plasmid DNA Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Viral Vector and Plasmid DNA Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Viral Vector and Plasmid DNA Revenue Market Share by Type (2021-2032) Figure 19. Global Viral Vector and Plasmid DNA Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Viral Vector and Plasmid DNA Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Viral Vector and Plasmid DNA Revenue Market Share by Application (2021-2032) Figure 22. North America Viral Vector and Plasmid DNA Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Viral Vector and Plasmid DNA Revenue Share by Type (2021-2032) Figure 24. North America Viral Vector and Plasmid DNA Revenue Share by Application (2021-2032) Figure 25. North America Viral Vector and Plasmid DNA Revenue Share by Country (2021-2032) Figure 26. United States Viral Vector and Plasmid DNA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Viral Vector and Plasmid DNA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Viral Vector and Plasmid DNA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Viral Vector and Plasmid DNA Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Viral Vector and Plasmid DNA Revenue Share by Type (2021-2032) Figure 31. Europe Viral Vector and Plasmid DNA Revenue Share by Application (2021-2032) Figure 32. Europe Viral Vector and Plasmid DNA Revenue Share by Country (2021-2032) Figure 33. Germany Viral Vector and Plasmid DNA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Viral Vector and Plasmid DNA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Viral Vector and Plasmid DNA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Viral Vector and Plasmid DNA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Viral Vector and Plasmid DNA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Viral Vector and Plasmid DNA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Viral Vector and Plasmid DNA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Viral Vector and Plasmid DNA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Viral Vector and Plasmid DNA Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Viral Vector and Plasmid DNA Revenue Share by Type (2021-2032) Figure 43. China Viral Vector and Plasmid DNA Revenue Share by Application (2021-2032) Figure 44. Asia Viral Vector and Plasmid DNA Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Viral Vector and Plasmid DNA Revenue Share by Type (2021-2032) Figure 46. Asia Viral Vector and Plasmid DNA Revenue Share by Application (2021-2032) Figure 47. Asia Viral Vector and Plasmid DNA Revenue Share by Region (2021-2032) Figure 48. Japan Viral Vector and Plasmid DNA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Viral Vector and Plasmid DNA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Viral Vector and Plasmid DNA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Viral Vector and Plasmid DNA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Viral Vector and Plasmid DNA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Viral Vector and Plasmid DNA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Viral Vector and Plasmid DNA Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Viral Vector and Plasmid DNA Revenue Share by Type (2021-2032) Figure 56. SAMEA Viral Vector and Plasmid DNA Revenue Share by Application (2021-2032) Figure 57. SAMEA Viral Vector and Plasmid DNA Revenue Share by Country (2021-2032) Figure 58. Brazil Viral Vector and Plasmid DNA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Viral Vector and Plasmid DNA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Viral Vector and Plasmid DNA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Viral Vector and Plasmid DNA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Viral Vector and Plasmid DNA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Viral Vector and Plasmid DNA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Viral Vector and Plasmid DNA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Viral Vector and Plasmid DNA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Viral Vector and Plasmid DNA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Viral Vector and Plasmid DNA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Viral Vector and Plasmid DNA Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Plasmid DNA
  • Viral Vector
Applications
  • Cancer
  • Virus Infection
  • Hereditary Disease
Companies covered
  • Brammer Bio
  • Oxford BioMedica
  • Cobra Biologics
  • FinVector
  • Lonza
  • BioReliance
  • MolMed
  • FUJIFILM Diosynth Biotechnologies
  • UniQure
  • Aldevron
  • Richter-Helm
  • Eurogentec
  • OBiO Technology
  • Yposkesi
  • Cell and Gene Therapy Catapult
  • MassBiologics
  • Biovian
  • VGXI
  • Gene Synthesis
  • PlasmidFactory
  • Jikai Gene

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Viral Vector and Plasmid DNA Market by Type
  3. 1.2.1 Global Viral Vector and Plasmid DNA Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Plasmid DNA
  5. 1.2.3 Viral Vector
  6. 1.3 Viral Vector and Plasmid DNA Market by Application
  7. 1.3.1 Global Viral Vector and Plasmid DNA Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Cancer
  9. 1.3.3 Virus Infection
  10. 1.3.4 Hereditary Disease
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Viral Vector and Plasmid DNA Market Dynamics
  1. 2.1 Viral Vector and Plasmid DNA Industry Trends
  2. 2.2 Viral Vector and Plasmid DNA Industry Drivers
  3. 2.3 Viral Vector and Plasmid DNA Industry Opportunities and Challenges
  4. 2.4 Viral Vector and Plasmid DNA Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Viral Vector and Plasmid DNA Market Perspective (2021-2032)
  2. 3.2 Global Viral Vector and Plasmid DNA Growth Trends by Region
  3. 3.2.1 Global Viral Vector and Plasmid DNA Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Viral Vector and Plasmid DNA Market Size by Region (2021-2026)
  5. 3.2.3 Global Viral Vector and Plasmid DNA Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Viral Vector and Plasmid DNA Revenue by Players
  2. 4.1.1 Global Viral Vector and Plasmid DNA Revenue by Players (2021-2026)
  3. 4.1.2 Global Viral Vector and Plasmid DNA Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Viral Vector and Plasmid DNA Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Viral Vector and Plasmid DNA Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Viral Vector and Plasmid DNA Key Players Headquarters & Area Served
  7. 4.4 Global Viral Vector and Plasmid DNA Players, Product Type & Application
  8. 4.5 Global Viral Vector and Plasmid DNA Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Viral Vector and Plasmid DNA Market CR5 and HHI
  11. 4.6.3 2025 Viral Vector and Plasmid DNA Tier 1, Tier 2, and Tier 3
5 Viral Vector and Plasmid DNA Market Size by Type
  1. 5.1 Global Viral Vector and Plasmid DNA Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Viral Vector and Plasmid DNA Revenue by Type (2021-2032)
  3. 5.3 Global Viral Vector and Plasmid DNA Revenue Market Share by Type (2021-2032)
6 Viral Vector and Plasmid DNA Market Size by Application
  1. 6.1 Global Viral Vector and Plasmid DNA Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Viral Vector and Plasmid DNA Revenue by Application (2021-2032)
  3. 6.3 Global Viral Vector and Plasmid DNA Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Brammer Bio
  2. 7.1.1 Brammer Bio Company Information
  3. 7.1.2 Brammer Bio Business Overview
  4. 7.1.3 Brammer Bio Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Brammer Bio Viral Vector and Plasmid DNA Product Portfolio
  6. 7.1.5 Brammer Bio Recent Developments
  7. 7.2 Oxford BioMedica
  8. 7.2.1 Oxford BioMedica Company Information
  9. 7.2.2 Oxford BioMedica Business Overview
  10. 7.2.3 Oxford BioMedica Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Oxford BioMedica Viral Vector and Plasmid DNA Product Portfolio
  12. 7.2.5 Oxford BioMedica Recent Developments
  13. 7.3 Cobra Biologics
  14. 7.3.1 Cobra Biologics Company Information
  15. 7.3.2 Cobra Biologics Business Overview
  16. 7.3.3 Cobra Biologics Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Cobra Biologics Viral Vector and Plasmid DNA Product Portfolio
  18. 7.3.5 Cobra Biologics Recent Developments
  19. 7.4 FinVector
  20. 7.4.1 FinVector Company Information
  21. 7.4.2 FinVector Business Overview
  22. 7.4.3 FinVector Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  23. 7.4.4 FinVector Viral Vector and Plasmid DNA Product Portfolio
  24. 7.4.5 FinVector Recent Developments
  25. 7.5 Lonza
  26. 7.5.1 Lonza Company Information
  27. 7.5.2 Lonza Business Overview
  28. 7.5.3 Lonza Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Lonza Viral Vector and Plasmid DNA Product Portfolio
  30. 7.5.5 Lonza Recent Developments
  31. 7.6 BioReliance
  32. 7.6.1 BioReliance Company Information
  33. 7.6.2 BioReliance Business Overview
  34. 7.6.3 BioReliance Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  35. 7.6.4 BioReliance Viral Vector and Plasmid DNA Product Portfolio
  36. 7.6.5 BioReliance Recent Developments
  37. 7.7 MolMed
  38. 7.7.1 MolMed Company Information
  39. 7.7.2 MolMed Business Overview
  40. 7.7.3 MolMed Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  41. 7.7.4 MolMed Viral Vector and Plasmid DNA Product Portfolio
  42. 7.7.5 MolMed Recent Developments
  43. 7.8 FUJIFILM Diosynth Biotechnologies
  44. 7.8.1 FUJIFILM Diosynth Biotechnologies Company Information
  45. 7.8.2 FUJIFILM Diosynth Biotechnologies Business Overview
  46. 7.8.3 FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  47. 7.8.4 FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Product Portfolio
  48. 7.8.5 FUJIFILM Diosynth Biotechnologies Recent Developments
  49. 7.9 UniQure
  50. 7.9.1 UniQure Company Information
  51. 7.9.2 UniQure Business Overview
  52. 7.9.3 UniQure Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  53. 7.9.4 UniQure Viral Vector and Plasmid DNA Product Portfolio
  54. 7.9.5 UniQure Recent Developments
  55. 7.10 Aldevron
  56. 7.10.1 Aldevron Company Information
  57. 7.10.2 Aldevron Business Overview
  58. 7.10.3 Aldevron Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Aldevron Viral Vector and Plasmid DNA Product Portfolio
  60. 7.10.5 Aldevron Recent Developments
  61. 7.11 Richter-Helm
  62. 7.11.1 Richter-Helm Company Information
  63. 7.11.2 Richter-Helm Business Overview
  64. 7.11.3 Richter-Helm Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Richter-Helm Viral Vector and Plasmid DNA Product Portfolio
  66. 7.11.5 Richter-Helm Recent Developments
  67. 7.12 Eurogentec
  68. 7.12.1 Eurogentec Company Information
  69. 7.12.2 Eurogentec Business Overview
  70. 7.12.3 Eurogentec Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Eurogentec Viral Vector and Plasmid DNA Product Portfolio
  72. 7.12.5 Eurogentec Recent Developments
  73. 7.13 OBiO Technology
  74. 7.13.1 OBiO Technology Company Information
  75. 7.13.2 OBiO Technology Business Overview
  76. 7.13.3 OBiO Technology Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  77. 7.13.4 OBiO Technology Viral Vector and Plasmid DNA Product Portfolio
  78. 7.13.5 OBiO Technology Recent Developments
  79. 7.14 Yposkesi
  80. 7.14.1 Yposkesi Company Information
  81. 7.14.2 Yposkesi Business Overview
  82. 7.14.3 Yposkesi Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Yposkesi Viral Vector and Plasmid DNA Product Portfolio
  84. 7.14.5 Yposkesi Recent Developments
  85. 7.15 Cell and Gene Therapy Catapult
  86. 7.15.1 Cell and Gene Therapy Catapult Company Information
  87. 7.15.2 Cell and Gene Therapy Catapult Business Overview
  88. 7.15.3 Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Product Portfolio
  90. 7.15.5 Cell and Gene Therapy Catapult Recent Developments
  91. 7.16 MassBiologics
  92. 7.16.1 MassBiologics Company Information
  93. 7.16.2 MassBiologics Business Overview
  94. 7.16.3 MassBiologics Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  95. 7.16.4 MassBiologics Viral Vector and Plasmid DNA Product Portfolio
  96. 7.16.5 MassBiologics Recent Developments
  97. 7.17 Biovian
  98. 7.17.1 Biovian Company Information
  99. 7.17.2 Biovian Business Overview
  100. 7.17.3 Biovian Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Biovian Viral Vector and Plasmid DNA Product Portfolio
  102. 7.17.5 Biovian Recent Developments
  103. 7.18 VGXI
  104. 7.18.1 VGXI Company Information
  105. 7.18.2 VGXI Business Overview
  106. 7.18.3 VGXI Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  107. 7.18.4 VGXI Viral Vector and Plasmid DNA Product Portfolio
  108. 7.18.5 VGXI Recent Developments
  109. 7.19 Gene Synthesis
  110. 7.19.1 Gene Synthesis Company Information
  111. 7.19.2 Gene Synthesis Business Overview
  112. 7.19.3 Gene Synthesis Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Gene Synthesis Viral Vector and Plasmid DNA Product Portfolio
  114. 7.19.5 Gene Synthesis Recent Developments
  115. 7.20 PlasmidFactory
  116. 7.20.1 PlasmidFactory Company Information
  117. 7.20.2 PlasmidFactory Business Overview
  118. 7.20.3 PlasmidFactory Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  119. 7.20.4 PlasmidFactory Viral Vector and Plasmid DNA Product Portfolio
  120. 7.20.5 PlasmidFactory Recent Developments
  121. 7.21 Jikai Gene
  122. 7.21.1 Jikai Gene Company Information
  123. 7.21.2 Jikai Gene Business Overview
  124. 7.21.3 Jikai Gene Viral Vector and Plasmid DNA Revenue and Gross Margin (2021-2026)
  125. 7.21.4 Jikai Gene Viral Vector and Plasmid DNA Product Portfolio
  126. 7.21.5 Jikai Gene Recent Developments
8 North America
  1. 8.1 North America Viral Vector and Plasmid DNA Revenue (2021-2032)
  2. 8.2 North America Viral Vector and Plasmid DNA Revenue by Type (2021-2032)
  3. 8.2.1 North America Viral Vector and Plasmid DNA Revenue by Type (2021-2026)
  4. 8.2.2 North America Viral Vector and Plasmid DNA Revenue by Type (2027-2032)
  5. 8.3 North America Viral Vector and Plasmid DNA Revenue Share by Type (2021-2032)
  6. 8.4 North America Viral Vector and Plasmid DNA Revenue by Application (2021-2032)
  7. 8.4.1 North America Viral Vector and Plasmid DNA Revenue by Application (2021-2026)
  8. 8.4.2 North America Viral Vector and Plasmid DNA Revenue by Application (2027-2032)
  9. 8.5 North America Viral Vector and Plasmid DNA Revenue Share by Application (2021-2032)
  10. 8.6 North America Viral Vector and Plasmid DNA Revenue by Country
  11. 8.6.1 North America Viral Vector and Plasmid DNA Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Viral Vector and Plasmid DNA Revenue by Country (2021-2026)
  13. 8.6.3 North America Viral Vector and Plasmid DNA Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Viral Vector and Plasmid DNA Revenue (2021-2032)
  2. 9.2 Europe Viral Vector and Plasmid DNA Revenue by Type (2021-2032)
  3. 9.2.1 Europe Viral Vector and Plasmid DNA Revenue by Type (2021-2026)
  4. 9.2.2 Europe Viral Vector and Plasmid DNA Revenue by Type (2027-2032)
  5. 9.3 Europe Viral Vector and Plasmid DNA Revenue Share by Type (2021-2032)
  6. 9.4 Europe Viral Vector and Plasmid DNA Revenue by Application (2021-2032)
  7. 9.4.1 Europe Viral Vector and Plasmid DNA Revenue by Application (2021-2026)
  8. 9.4.2 Europe Viral Vector and Plasmid DNA Revenue by Application (2027-2032)
  9. 9.5 Europe Viral Vector and Plasmid DNA Revenue Share by Application (2021-2032)
  10. 9.6 Europe Viral Vector and Plasmid DNA Revenue by Country
  11. 9.6.1 Europe Viral Vector and Plasmid DNA Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Viral Vector and Plasmid DNA Revenue by Country (2021-2026)
  13. 9.6.3 Europe Viral Vector and Plasmid DNA Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Viral Vector and Plasmid DNA Revenue (2021-2032)
  2. 10.2 China Viral Vector and Plasmid DNA Revenue by Type (2021-2032)
  3. 10.2.1 China Viral Vector and Plasmid DNA Revenue by Type (2021-2026)
  4. 10.2.2 China Viral Vector and Plasmid DNA Revenue by Type (2027-2032)
  5. 10.3 China Viral Vector and Plasmid DNA Revenue Share by Type (2021-2032)
  6. 10.4 China Viral Vector and Plasmid DNA Revenue by Application (2021-2032)
  7. 10.4.1 China Viral Vector and Plasmid DNA Revenue by Application (2021-2026)
  8. 10.4.2 China Viral Vector and Plasmid DNA Revenue by Application (2027-2032)
  9. 10.5 China Viral Vector and Plasmid DNA Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Viral Vector and Plasmid DNA Revenue (2021-2032)
  2. 11.2 Asia Viral Vector and Plasmid DNA Revenue by Type (2021-2032)
  3. 11.2.1 Asia Viral Vector and Plasmid DNA Revenue by Type (2021-2026)
  4. 11.2.2 Asia Viral Vector and Plasmid DNA Revenue by Type (2027-2032)
  5. 11.3 Asia Viral Vector and Plasmid DNA Revenue Share by Type (2021-2032)
  6. 11.4 Asia Viral Vector and Plasmid DNA Revenue by Application (2021-2032)
  7. 11.4.1 Asia Viral Vector and Plasmid DNA Revenue by Application (2021-2026)
  8. 11.4.2 Asia Viral Vector and Plasmid DNA Revenue by Application (2027-2032)
  9. 11.5 Asia Viral Vector and Plasmid DNA Revenue Share by Application (2021-2032)
  10. 11.6 Asia Viral Vector and Plasmid DNA Revenue by Country
  11. 11.6.1 Asia Viral Vector and Plasmid DNA Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Viral Vector and Plasmid DNA Revenue by Country (2021-2026)
  13. 11.6.3 Asia Viral Vector and Plasmid DNA Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Viral Vector and Plasmid DNA Revenue (2021-2032)
  2. 12.2 SAMEA Viral Vector and Plasmid DNA Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Viral Vector and Plasmid DNA Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Viral Vector and Plasmid DNA Revenue by Type (2027-2032)
  5. 12.3 SAMEA Viral Vector and Plasmid DNA Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Viral Vector and Plasmid DNA Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Viral Vector and Plasmid DNA Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Viral Vector and Plasmid DNA Revenue by Application (2027-2032)
  9. 12.5 SAMEA Viral Vector and Plasmid DNA Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Viral Vector and Plasmid DNA Revenue by Country
  11. 12.6.1 SAMEA Viral Vector and Plasmid DNA Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Viral Vector and Plasmid DNA Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Viral Vector and Plasmid DNA Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst